Analyst Ratings for Coherus BioSciences
Portfolio Pulse from Benzinga Insights
Coherus BioSciences (NASDAQ:CHRS) has received 11 analyst ratings in the last quarter, with 10 being bullish and 1 somewhat bullish. The average price target is $20.36, representing a significant upside from the current price of $5.225. This average price target is a 6.61% decrease from the previous average of $21.80.
August 04, 2023 | 2:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Coherus BioSciences has received positive analyst ratings, which could lead to an increase in its stock price.
Analyst ratings often influence investor sentiment and can impact a company's stock price. In this case, Coherus BioSciences has received predominantly bullish ratings, which could lead to increased investor interest and a potential rise in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100